Compare · LEVI vs SILO
LEVI vs SILO
Side-by-side comparison of Levi Strauss & Co (LEVI) and Silo Pharma Inc. (SILO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LEVI and SILO operate in Apparel (Consumer Discretionary), so they compete in similar markets.
- LEVI is the larger of the two at $9.37B, about 1540.0x SILO ($6.1M).
- Over the past year, LEVI is up 16.5% and SILO is down 49.1% - LEVI leads by 65.6 points.
- SILO has been more active in the news (10 items in the past 4 weeks vs 4 for LEVI).
- LEVI has more recent analyst coverage (25 ratings vs 0 for SILO).
- Company
- Levi Strauss & Co
- Silo Pharma Inc.
- Price
- $24.36-2.54%
- $4.83+0.31%
- Market cap
- $9.37B
- $6.1M
- 1M return
- +2.29%
- -24.28%
- 1Y return
- +16.50%
- -49.13%
- Industry
- Apparel
- Apparel
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 4
- 10
- Recent ratings
- 25
- 0
Levi Strauss & Co
Levi Strauss & Co. operates as an apparel company. It designs, markets, and sells jeans, casual and dress pants, tops, shorts, skirts, jackets, footwear, and related accessories for men, women, and children in the Americas, Europe, and Asia. The company sells its products under the Levi's, Dockers, Signature by Levi Strauss & Co., and Denizen brands; and also licenses its Levi's and Dockers trademarks for various product categories, including footwear, belts, wallets and bags, outerwear, sweaters, dress shirts, kids wear, sleepwear, and hosiery. The company sells its products through third-party retailers, such as department stores, specialty retailers, third-party e-commerce sites, and franchisees who operate brand-dedicated stores; and directly to consumers through various formats, including company-operated mainline and outlet stores, company-operated e-commerce sites, and select shop-in-shops located in department stores and other third-party retail locations. It operates approximately 3,100 brand-dedicated stores and shop-in-shops. The company was founded in 1853 and is headquartered in San Francisco, California.
Latest LEVI
- SEC Form 10-Q filed by Levi Strauss & Co
- Levi Strauss & Co filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Levi Strauss & Co. Reports Second-Quarter Results
- Levi Strauss & Co. to Webcast Second Quarter 2026 Earnings Conference Call
- Levi Strauss & Co filed SEC Form 8-K: Leadership Update
- Large owner Haas Robert D. converted options into 202,135 shares and sold $4,855,606 worth of shares (202,135 units at $24.02) (SEC Form 4)
- Large owner Peter E. Haas Jr. Family Fund converted options into 145,662 shares and sold $3,497,112 worth of shares (145,662 units at $24.01) as part of a pre-agreed trading plan (SEC Form 4)
- Large owner Haas Margaret E. converted options into 47,721 shares and sold $1,145,891 worth of shares (47,721 units at $24.01) as part of a pre-agreed trading plan (SEC Form 4)
- Large owner Haas Robert D. converted options into 492,033 shares and sold $11,860,121 worth of shares (492,033 units at $24.10) (SEC Form 4)
- SEC Form 4 filed by Large owner Haas Robert D.
Latest SILO
- SEC Form D filed by Silo Pharma Inc.
- Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
- Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- SEC Form SCHEDULE 13G filed by Silo Pharma Inc.
- Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
- SEC Form DEFA14A filed by Silo Pharma Inc.
- SEC Form DEF 14A filed by Silo Pharma Inc.
- Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
- Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial